| abstract |
Novel isolated human rotaviruses are disclosed. The novel human rotaviruses in accordance with the instant invention have derived their genomic segments from parental strains of different genogroups and/or serotypes. The novel rotaviruses of the present invention are designated as HRV 248, HRV 456, HRV 89-12C2, HRV 408 and CJN. The human rotavirus designated as HRV 89-12C2, HRV 408, HRV 248 and CJN have been deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852, and have been assigned the following ATCC accession nos. VR 2272, VR 2273, VR 2274 and VR 2275, respectively. Also disclosed are novel vaccines formulated with the human rotaviruses of the instant invention, and methods of vaccinating humans against human rotaviruses of multiple serotypes with such vaccines. A novel method for boosting the titers of neutralizing antibodies and expanding the memory of the cells generated which express the neutralizing antibody formed following primary vaccination for preventing rotavirus illnesses induced by human rotaviruses of all serotypes comprising revaccinating the primed subjects with a heterotypic non-human animal rotavirus vaccine, such as with a WC3 bovine vaccine, is also disclosed. |